" class="no-js "lang="en-US"> Mammoth Scientific - Medtech Alert
Monday, October 20, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Mammoth Scientific | Pharmtech Focus

Mammoth Scientific

About Mammoth Scientific

Mammoth Scientific

Mammoth invests in companies with world changing technologies, proven intellectual property and founding teams with the grit to succeed. Our team, process and investment thesis guide our portfolios to maximize success and reduce the friction that can hold new companies back.

Related Story

Fundraising

 Mammoth Scientific Launches $100 Million Venture Capital Fund | Pharmtech Focus

Mammoth Scientific Launches $100 Million Venture Capital Fund

July 15 2021

Mammoth™ Scientific, a health science and technology venture capital firm, announced the launch of a […]